000 01340 a2200373 4500
005 20250516001448.0
264 0 _c20101129
008 201011s 0 0 eng d
022 _a1759-4782
024 7 _a10.1038/nrclinonc.2010.141
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBocchia, Monica
245 0 0 _aComplete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination.
_h[electronic resource]
260 _bNature reviews. Clinical oncology
_cOct 2010
300 _a600-3 p.
_bdigital
500 _aPublication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aCancer Vaccines
_xtherapeutic use
650 0 4 _aFemale
650 0 4 _aFusion Proteins, bcr-abl
_xblood
650 0 4 _aHumans
650 0 4 _aInterferon-alpha
_xtherapeutic use
650 0 4 _aLeukemia, Myelogenous, Chronic, BCR-ABL Positive
_xblood
650 0 4 _aMiddle Aged
650 0 4 _aVaccination
700 1 _aDefina, Marzia
700 1 _aAprile, Lara
700 1 _aIppoliti, Micaela
700 1 _aCrupi, Rosaria
700 1 _aRondoni, Michela
700 1 _aGozzetti, Alessandro
700 1 _aLauria, Francesco
773 0 _tNature reviews. Clinical oncology
_gvol. 7
_gno. 10
_gp. 600-3
856 4 0 _uhttps://doi.org/10.1038/nrclinonc.2010.141
_zAvailable from publisher's website
999 _c20141659
_d20141659